Your browser doesn't support javascript.
loading
Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality.
Madsen, Kayla; Lee, Katherine; Chen, Shiyi; Chen, Carol; Law, Arjun Datt; Gerbitz, Armin; Kumar, Rajat; Kim, Dennis; Lam, Wilson; Pasic, Ivan; Viswabandya, Auro; Michelis, Fotios V; Nampoothiri, Ram Vasudevan; Lipton, Jeffrey H; Novitzky-Basso, Igor; Mattsson, Jonas.
Afiliación
  • Madsen K; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lee K; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Chen S; Department of Biostatistics, University Health Network, Toronto, Canada.
  • Chen C; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Law AD; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Gerbitz A; Department of Medicine, University of Toronto, Toronto, Canada.
  • Kumar R; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kim D; Department of Medicine, University of Toronto, Toronto, Canada.
  • Lam W; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Pasic I; Department of Medicine, University of Toronto, Toronto, Canada.
  • Viswabandya A; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Michelis FV; Department of Medicine, University of Toronto, Toronto, Canada.
  • Nampoothiri RV; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lipton JH; Department of Medicine, University of Toronto, Toronto, Canada.
  • Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Mattsson J; Department of Medicine, University of Toronto, Toronto, Canada.
Support Care Cancer ; 31(10): 564, 2023 Sep 07.
Article en En | MEDLINE | ID: mdl-37676349
ABSTRACT

PURPOSE:

Allogeneic stem cell transplant (allo-HSCT) patients are at risk of malnutrition and weight loss from impaired oral intake resulting from gastrointestinal toxicities, dysgeusia, and psychological effects.

METHODS:

A retrospective review of 264 adult patients transplanted at Princess Margaret Cancer Centre who achieved relapse-free survival up to 3 months after allo-HSCT was performed.

RESULTS:

Overall incidence of patients who experienced WL (WL) ≥ 10% from HSCT to 3-month post-transplant was 45.9% and from HSCT to 6 months was 56.6%. Patients with ≥ 10% WL from allo-HSCT at 3 months and 6 months had similar 2-year overall survival (OS) compared to those with < 10% WL, 55.7% vs 62.8% (HR = 1.38, p = 0.11) and 71.1% vs 77.2% (HR = 1.37, p = 0.27), respectively. Patients with ≥ 10% WL 3 and 6 months from allo-HSCT also had similar 2-year relapse-free survival (RFS) compared to those with < 10% WL, 48.1% vs 55.8% (HR = 1.26, p = 0.22), and 62.7% vs 69.8% (HR = 1.29, p = 0.31), respectively. The 2-year transplant-related mortality (TRM) was higher for those with ≥ 10% WL from allo-HSCT to 3 months, 35.4% vs 16.9% (HR = 2.39, p = 0.0007) and 6 months, 22% vs 8% (HR = 3.1, p = 0.0034). Although statistical significance was not observed for OS or RFS, patients who experienced ≥ 10% WL 3- and 6-months post allo-HSCT experienced higher 2-year TRM. These results highlight the importance of early intervention and close monitoring of weight post allo-HSCT.

CONCLUSION:

Approaches to WL post allo-HSCT should be multifaceted and include members of the interdisciplinary team in order to decrease TRM.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Desnutrición Tipo de estudio: Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Desnutrición Tipo de estudio: Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Canadá